UCLA TECHNOLOGY DEVELOPMENT GROUP

LA BIOSCIENCE ECOSYSTEM SUMMIT TWENTY23™

UCLA

THURSDAY

MAY 25, 2023

UCLA MEYER AND RENEE LUSKIN CONFERENCE CENTER

LA BIOSCIENCE ECOSYSTEM SUMMIT TWENTY23™ UCLA

SPONSORS

UCLA TECHNOLOGY DEVELOPMENT GROUP

INNOVATOR SPONSOR

AMGEN

Kite A GILEAD Company

UCLA GOLD SPONSOR

Allogene THERAPEUTICS

AUTOBAHN LABS

Breakthrough PROPERTIES

FOLEY HOAG

Johnson & Johnson INNOVATION

MCKOOL SMITH

NORTON ROSE FULBRIGHT

PEARL COHEN

Pfizer

TORL BIOTHERAPEUTICS

xencor

BRUIN BLUE SPONSOR

A2 BIO

ABBOTT CONSTRUCTION

APPIA BIO

charles river

cvent

GATES & COOPER LLP INTELLECTUAL PROPERTY LAW

Genentech A Member of the Roche Group

IMPACT BIO

LANDMARK BIO™ MANUFACTURING BREAKTHROUGHS

MERCK

NIXON PEABODY

REGIONAL SPONSOR

City of Hope

CSL

Keck School of Medicine of USC

UCLA Jonsson Comprehensive Cancer Center

Takeda

Yuyu

UCLA BEAR SPONSOR

PERKINSCOIE COUNSEL TO GREAT COMPANIES

MEDIA SPONSOR

LA ist

COMMUNITY PARTNER

ALEXANDRIA

BioscienceLA

Biocom California

BIOTECH CONNECTION LOS ANGELES

CALIFORNIA LIFE SCIENCES

CAL STATE LA

Caltech

Cedars Sinai

CIRM

CNSI

UCLA CTSI

LARTA INSTITUTE

THE LUNDQUIST INSTITUTE

NIMBL

Nucleate

POSTDOCTORAL ASSOCIATION at UCLA

SoCalBio Southern California Biomedical Council

UCLA David Geffen School of Medicine

UCLA Health

UCLA TECHNOLOGY DEVELOPMENT GROUP

LA BIOSCIENCE ECOSYSTEM SUMMIT TWENTY23™ UCLA

WELCOME

Dear LABEST Attendees,

UCLA Technology Development Group welcomes you to the 5th Annual LABEST conference. This year's event marks a year of growth for the life science industry in our region and our event becoming the industry's leading summit in Southern California.

We built LABEST as an international showcase for doing business in our region, as part of our global outreach. We are pleased to host Director General Daren Tang from the UN World Intellectual Property Organization and Dr. Albert Bourla Chairman and CEO of Pfizer as our keynote speakers.

The UC system has always been a strong collaborator translating scientific ideas, concepts and invention to various products. Cutting edge science performed in labs on UC campuses across California is making a positive impact on people lives throughout the world. I am excited that Regents Board Chair Leib, Regent Park and Chancellor Block, will speak in a fireside chat on how academia plays an important role in the bioscience ecosystem and how the UC system plans to be at the cutting edge of this process.

In addition to our blockbuster panels featuring leaders of the industry and local hospitals, there will be dozens of scientific presentations, startups pitches, VC panel and infrastructure spotlights.

We are grateful to our sponsors especially to our partnership with Amgen and Kite.

Thank you for being a part of this exceptional day.

Amir Naiberg
Associate Vice Chancellor, CEO & President
UCLA Technology Development Group

#LABEST2023 | tdg.ucla.edu

LA BIOSCIENCE ECOSYSTEM SUMMIT TWENTY23 UCLA

LUSKIN
CONFERENCE CENTER

UCLA TECHNOLOGY DEVELOPMENT GROUP

MEETING SPACE: LEVEL 1



LA BIOSCIENCE ECOSYSTEM SUMMIT TWENTY23™ UCLA

LUSKIN
CONFERENCE CENTER

UCLA TECHNOLOGY DEVELOPMENT GROUP

MEETING SPACE: LEVEL 2



Our Mission:
To Serve Patients

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

To learn more visit www.amgen.com.

AMGEN

LA BIOSCIENCE ECOSYSTEM SUMMIT TWENTY23™
UCLA

TABLE OF CONTENTS

WELCOME

Thursday, May 25, 2023
UCLA Meyer and Renee Luskin Conference Center

SPECIAL SERVICES

The Cappuccino Connection
espresso bar and lounge
UCLA TDG Patio, 1st floor

Charging Stations
two in Centennial Prefunction Area, 1st floor
two in each Lounge, 2nd floor
three on Centennial Terrace, 3rd floor

Lounges
UCLA TDG Patio, 1st floor
2nd floor, North Wing
2nd floor, South Wing

Pearl Cohen Poster Competition Awardees
Entrepreneur, 2nd floor, South Wing

Exhibitors
1st floor
2nd floor, South Wing

Institutional Partner Rooms
City of Hope and USC
2nd floor, North Wing

WIFI

Network
Luskin_Meeting

Password
LCC2023

#LABEST2023 | tdg.ucla.edu

Changing the way cancer is treated.

Kite's singular focus is cell therapy to treat and potentially cure cancer.

Kite is a proud supporter of LABEST and its work to showcase bioscience innovation in Los Angeles.

Kite
A GILEAD Company

MAIN TRACK

Centennial Ballroom, 1st Floor

REGISTRATION OPENS

7:30am **REGISTRATION OPENS**
South Courtyard/1st Floor

BREAKFAST FEATURING THE CAPPUCCINO CONNECTION
Centennial Patio/1st Floor

7:30am-11:45am **VISIT THE UCLA HEALTH HOMELESS HEALTHCARE COLLABORATIVE MOBILE CLINIC ON DISPLAY**
The specially equipped vehicle provides much-needed services to unhoused people throughout Los Angeles.
Main Entrance Driveway/1st Floor

MORNING SESSION

Centennial Ballroom/1st Floor

Emcee: Judy Fortin, Chief of Communications, UCLA Health

8:30am **WELCOMES BY**
- UCLA Chancellor Gene Block
- LABEST 2023 Innovator Sponsors Introduction by Mark Wisniewski, Senior Director, Bio Pharmaceuticals, UCLA TDG
  - Jessica Droge, Vice President of Business Development, Head of Global Search & Evaluation, Amgen
  - Aliya Z. Omer, Vice President of Corporate Development & Head of Global Portfolio and Program Strategy, Kite, a Gilead Company

8:45am **"FIRESIDE CHAT" WITH THE UNIVERSITY OF CALIFORNIA BOARD OF REGENTS AND UCLA CHANCELLOR**
The importance of academic research and intellectual property

Introduction by Amir Naiberg, AVC, CEO and President, UCLA TDG
- Moderated by Judy Fortin
- UCLA Chancellor Gene Block
- Chair of the Board of Regents, Richard Leib
- Regent Lark Park

9:15am **KEYNOTE ADDRESS**
Introduction by Arie Belldegrun, Roy and Carol Doumani Chair in Urologic Oncology, UCLA

- Dr. Albert Bourla, Chairman and CEO, Pfizer

9:40am **KEYNOTE ADDRESS**
Introduction by Andrei Iancu, Partner, Irell & Manella LLP
- Director General Daren Tang, WIPO

10:05am **LA HOSPITAL LEADERS INNOVATING FOR FUTURE SUCCESS PANEL**
A panel discussion with Hospital CEOs from our long-standing LABEST partners in the Los Angeles area, covering challenges, accomplishments, and what the future has in store for Hospitals.

- Moderated by Judy Fortin
- Hosted by Johnese Spisso, President of UCLA Health, CEO of UCLA Hospital System and Associate Vice Chancellor of UCLA Health Sciences

Panelists include:
- Dr. Elaine Batchlor, CEO, MLK Community Healthcare
- Dr. Jeffrey Golden, Director, Burns and Allen Research Institute, Vice Dean for Research and Graduate Education, Cedars-Sinai
- Mr. Chad Lefteris, CEO, UCI Health
- Dr. Anish Mahajan, CEO and Chief Medical Officer, Harbor-UCLA Medical Center

Schedule and Speakers subject to change.

MAIN TRACK
CONTINUED

Centennial Ballroom, 1st Floor

10:50am **MEET THE LEADERS IN THE BUSINESS OF LIFE SCIENCES PANEL**

A panel discussion with CEOs of Life Sciences companies discussing recent discoveries, new diseases and drug discoveries in the pipeline.

Introduction by Dr. John Mazziotta, Vice Chancellor, UCLA Health Sciences, CEO, UCLA Health

- Moderated by Arie Belldegrun, Roy and Carol Doumani Chair in Urologic Oncology, UCLA,
  Director and Founder of The UCLA Institute of Urologic Oncology,
  Co-Founder and Sr. Managing Director, Vida Ventures,
  Executive Chairman and Co-Founder, Allogene

Panelists include:

- Norbert Bischofberger, President and CEO, Kronos Bio
- David Chang, President, CEO, and Co-Founder, Allogene
- Mark Cobbold, MD, PhD, VP Discovery Oncology, Head of Oncology Cell Therapy, AstraZeneca
- Aamir Malik, Chief Business Innovation Officer, Executive Vice President, Pfizer
- Dennis J. Slamon, MD, PhD, Director of Clinical/Translational Research, UCLA Jonsson Comprehensive Cancer Center

12:00pm **PEARL COHEN POSTER AWARDS ANNOUNCEMENT**

This competition provides a unique opportunity to showcase the undergraduate and graduate bioscience research program to pharma and biotech industry leaders' entrepreneurs, and investors.

- Announced by Michael Yamin, Scientific Advisor, Pearl Cohen

PEARL COHEN POSTER CONTESTANTS

Entrepreneur/South 2nd Floor

11:30am-5:30pm **VIEW FIRST AND SECOND PLACE WINNING POSTERS**

LUNCH

11:30am-12:45pm **EARLY LUNCH**

Open to General Attendees
Legacy and Optimist, 2nd Floor

12:00pm- **LUNCH | EXHIBITORS | NETWORKING**

1:30pm Additional Lunch Locations Open to General Attendees:

- UCLA TDG Patio, 1st Floor
- Plateia, 1st Floor near Main Entrance

Schedule and Speakers subject to change.

UCLA TDG LEARNING LOUNGE

SPONSORED BY MCKOOL SMITH

Optimist, 2nd floor, North Wing

UCLA TDG LEARNING LOUNGE

Optimist, 2nd floor, North Wing

Sponsored by McKool Smith

1:00pm **WELCOME BY**

Alfonso Chan, Principal, McKool Smith

1:01pm **VENTURE CAPITAL PANEL**

This panel aims to explore the opportunities, challenges, and evolving landscape for biotech venture creation in Los Angeles. The panel will focus on the Los Angeles biotech ecosystem.

- Moderated by Josh Green, Chairman Emeritus, National Venture Capital Association

Panelists include:

- Anurag Agarwal, Partner Life Science, Osage University Partners
- Michael Fritz, Principal, McKool Smith
- Sean Harper, Founding Managing Director, Westlake Village BioPartners
- D.A. Wallach, General Partner & Co-Founder, Time BioVentures

2:10pm **NETWORKING BREAK**

2:30pm **IMPROVING YOUR PRESENTATION SKILLS**

Want to learn how to improve your skills and present like a pro? Join McKool Smith's Steven Pollinger for a workshop to help you craft your written and verbal remarks.

- Steven J. Pollinger, Principal, McKool Smith

3:05pm **INDUSTRY SPONSORED RESEARCH PANEL**

An interactive discussion on the best practices for faculty to obtain Sponsored Research Agreements with the biopharma industry and how to maintain a successful collaboration.

- Moderated by Angela Coxon, VP of Oncology Research, Amgen

Panelists include:

- John Desjarlais, Executive Vice President, Research & Chief Scientific Officer, Xencor, Inc.
- Mark Jurgens, Head of External Scientific Collaborations, Kite, a Gilead Company
- Helen Kim, Executive Director, Head of Technology, Business Development, Amgen
- Sanjay Mistry, Vice President, Venture Investments New Company Creation, Johnson & Johnson Innovation, JJDC, Inc.
- Christina Ondrick, Principal, McKool Smith
- Karla Zepeda, ISR Director, UCLA TDG
- Ran Zheng, CEO, Landmark Bio

4:30pm **INTELLECTUAL PROPERTY**

Why do technology transfer offices exist?

Discussion between UCLA TDG Chief IP Officer, Charan Arora and McKool Smith Principals, Steven J. Pollinger and Josh Budwin

4:50pm **PATENT LITIGATION PANEL**

This panel aims to provide law firms' perspectives on patent litigation and share examples of cases that could've been avoided and how. • Moderated by Josh Budwin, Principal, McKool Smith

Panelists include:

- Blair Jacobs, Principal, McKool Smith
- Patrick Maloney, Senior Associate, Armond Wilson LLP
- Mark Siegmund, Partner, Cherry Johnson Siegmund James
- Peter Tong, Partner, Russ August & Kabat

Schedule and Speakers subject to change.

STARTUP ECOSYSTEM SHOWCASE

Illumination, 2nd floor, South Wing

Sponsored by Abbott Construction and Breakthrough Properties

Built by The Lundquist Institute and Larta Institute
Illumination, 2nd floor, South Wing

1:45pm SHOWCASE CO-MODERATORS WELCOME BY
- Keith Hoffman, PhD, Senior Advisor for Business Development, The Lundquist Institute
- Rohit K. Shukla, Founder & CEO, Larta Institute

1:46pm SHOWCASE KEYNOTE
- Susie Harborth, Chief Business Officer, Breakthrough Properties

2:00pm INCUBATOR AND STARTUP RESOURCES PANEL

Select Los Angeles incubators will highlight their resources and top startups. They will participate in a panel discussion covering topics like: What is needed in our ecosystem? How can they improve? How can local government help us elevate Los Angeles on the map?

- Additional, Guest, Moderator: Dave Whelan, CEO, BioscienceLA

Panelists include:
- Danielle Bogdanowicz, VP of Business Operations & Strategy, Biolabs at the Lundquist Institute
- Johnny Lam, VP Business Development, Scale Health
- Nikki Lin, Director of Entrepreneurship & Commercialization, Magnify at CNSI, UCLA
- Howard Xu, Director, Incubator Development and Programming, Cal State LA BioSpace

2:45pm NETWORKING BREAK

3:00pm ADAPTIVE REUSE FOR BIOSCIENCE IN LOS ANGELELS
- Marcella Ayala, Director of Business Development, Abbott Construction

3:15pm REAL ESTATE AND BIOSCIENCE PANEL

Real estate developers will discuss some challenges and successes they've experienced in aiding the growth of Los Angeles' startup ecosystem.

- Additional Guest moderator: Larry Lantero, Vice President, Abbott Construction

Panelists include:
- Marissa Goldberg, CEO, Doheny Eye Institute
- Howard Kozloff, CEO and Founder, Noblespace
- Peter Moglia, CEO and Co-Chief Investment Officer, Alexandria Real Estate Equities, Inc.
- Nancy Moses, Principal, Trammell Crow Company
- Chris Sinfield, Vice Chairman, Cushman & Wakefield

4:15pm NETWORKING BREAK

4:30pm CITIES AND MUNICIPALITIES TO WATCH FOR

Panelists will discuss what makes proposed projects appealing for city/government approval and what is needed to continue working together in making Los Angeles the next big bioscience hub.

- Additional, Guest Moderator: Stephen Cheung, CEO, LAEDC

Panelists include:
- Fran Fulton, Economic Development Manager, Office of the City Manager, City of Torrance
- Teresa Garcia, Senior Project Manager, Economic Development Division, Office of the City Manager, City of Pasadena
- Kelly LoBianco, Director, LA County Department of Economic Opportunity

Schedule and Speakers subject to change.

NUCLEATE AND UCLA PDA SHOWCASE

Exploration, 2nd Floor, North Wing

Built by Nucleate
Exploration, 2nd Floor, North Wing

2:00pm WELCOME AND INTRODUCTIONS TO NUCLEATE AND PDA

- Nucleate Activator Program Pitch Showcase. The program provides a proven and unparalleled competitive advantage to begin the lab-to-market journey. The primary program begins with a "mutual-matching" team formation phase, followed by workshops and mentor office hours, culminating in a final pitch showcase at LABEST.

Pitch Showcase Judges:

- Aiden Aceves, Vice President of Investments, Insight Partners
- Alan Block, Principal, McKool Smith
- Paul Hughes, Executive Director of Research, Amgen Inc.
- Seth Lieblich, Principal, 8VC
- Beverly Lu, Investment Manager, Health, Emerson Collective

2:10pm PITCH TEAM #1 - SERENITY
Wearable Stress Monitoring and Therapy

2:22pm PITCH TEAM #2 - SEMPER
Mammalian ratio-tunable polycistronic RNA expression platform for in vitro and in vivo delivery

2:34pm PITCH TEAM #3 - OSEM
Rapid prototyping with customizable tools to develop nanodrugs

2:46pm PITCH TEAM #4 - ACCELERATED MAGNETICS
Magnetic external control system for enhanced drug screening capabilities

2:58pm PITCH TEAM #5 - METABA
Novel adjunctive therapeutic for tuberculosis targeting metabolism

3:10pm AMGEN GOLDEN TICKET ANNOUNCEMENT

3:14 pm NETWORKING BREAK AND PITCH DELIBERATIONS

3:40pm IMPROVE YOUR PRESENTATION SKILLS

- Judy Fortin, Chief of Communications, UCLA Health

4:20pm NETWORKING BREAK

4:35pm INDUSTRY SPONSORED RESEARCH PANEL
An interactive discussion on the best practices for postdocs to obtain Sponsored Research Agreements with the biopharma industry and how to maintain a successful collaboration.

- Moderated by Tom Novak, CSO, Autobahn Labs

Panelists include:

- Dan Gorman, Principal Scientist & Group Leader, Merck
- Jessica Malloy, External Research Program Lead, Kite, a Gilead Company
- Ryan Potts, Scientific VP of Research and Chair of R&D Postdoc Program, Amgen
- Elizabeth Wu, Director, Early Innovation Partnering, Johnson & Johnson Innovation

Schedule and Speakers subject to change.

COMPANY SUMMARIES

Serenity - Medical Devices/Digital Health

SUMMARY: We have developed a wearable device that monitors physiological inputs correlating to psychological stress, which fits the PANAS questionnaire model to quantify stress in a continuous fashion. Using this information, our device will be able to personalize a therapeutic model for stress reduction via acoustics as thermal pads.

SEMPERTools/Techniques

SUMMARY: Here we propose a novel solution, it allows for expression of multiple proteins from a single mRNA, and provides a user-friendly framework to arbitrarily and predictably tune translated product stoichiometry. We named this novel approach "Stoichiometric Expression of Messenger Polycistrons by Eukaryotic Ribosomes" (SEMPER). We aim to demonstrate that SEMPER can be used with engineered synthetic RNAs, which can be transfected directly in vivo. We would like to utilize this technology to form a company, which specializes in development and production of vaccines, therapeutics and engineered cell systems, which require precise control of production from genetically complex payloads.

OSEM - Medical Devices/Tools

SUMMARY: OSEM is a rapid prototyping platform for nanodrugs. The OSEM platform employs proprietary micro-cartridges that enable scientists to easily automate different fluidic processes for nanodrug development, such as nanoparticle synthesis, nanoparticle concentration, and buffer exchange.

Accelerated Magnetics - Research Tools

SUMMARY: Our technology turns the microscope sample stage into an electromagnet that, in conjunction with the magnetogel, allows us to study the effect of material changes on the cells and biological constructs grown within the material in-real time. Through functionalizing the microscope stage, we developed a technology that revolutionizes the cornerstone of scientific investigation.

METABA - Therapeutics

SUMMARY: We plan to develop a novel Tuberculosis (TB) drug targeting a key enzyme in persister cells that will act as an adjunctive therapeutic, making the current antibiotic regimen more effective and shortening the length of treatment.

LA BIOMANUFACTURING SHOWCASE

Legacy, 2nd Floor, South Wing

Built by the California Institute for Regenerative Medicine (CIRM) and the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)

Legacy, 2nd Floor, South Wing

2:30pm **WELCOME BY**

- Shyam Patel, Senior Director of Business Development and Alliance Management, CIRM

2:32pm **SHOWCASE KEYNOTE**

- Mitra Cruz, VP of Manufacturing, Site Head – El Segundo Manufacturing Facility, Kite, a Gilead Company

3:05pm **WHAT TECHNOLOGY ADVANCEMENTS ARE NEEDED TO DELIVER ACCESSIBLE AND AFFORDABLE ADVANCED THERAPIES TO PATIENTS?**

- Moderated by Gregory Theyel, PhD, Director, Biomedical Manufacturing Network

Panelists include:

- Mohamed Abou-el-Enein, Executive Director, Joint USC/CHLA Cell Therapy Program, USC
- Sylvain Roy, CTO, ImmPACT Bio
- Dhruv Sareen, Executive Director, Cedars-Sinai Biomanufacturing Center
- Dawn Ward, Associate Clinical Professor, UCLA David Geffen School of Medicine

3:50pm **NETWORKING BREAK**

4:10pm **HOW THE GROWING LA BIOMANUFACTURING ECOSYSTEM IS WELL POSITIONED TO ADVANCE CELL AND GENE THERAPY DEVELOPMENT**

- Moderated by Gregory Theyel, PhD, Director, Biomedical Manufacturing Network

Panelists include:

- Taby Ahsan, Vice President, Cell and Gene Therapy Operations, City of Hope
- Gargi Ghosh, Associate Professor, Bioprocessing Program, Keck Graduate Institute
- Elie Hanania, PhD, VP of Process Development Viral Vector Technologies, Avid Bioservices
- Brianna Schoen, PhD, Sr. Scientific Director, Charles River Laboratories, Cell Solutions

Schedule and Speakers subject to change.

NON-DILUTIVE FUNDING SEMINAR

Enlightenment, 2nd Floor, South Wing

Built by BioscienceLA and Johnson & Johnson Innovation – JLABS, with NIH

Enlightenment, 2nd Floor, South Wing

Opportunities for faculty & startups to learn about non-dilutive funding opportunities, including SBIR awards, translational grant programs, and others.

- Opportunities to connect with representatives from select funding programs

3:00pm WELCOME & INTRODUCTIONS

- Dave Whelan, CEO, BioscienceLA
- LCDR Michael Banyas, USPHS, MPA, MA, SBIR Program Manager, National Institute of Minority and Health Disparities

3:10pm NIH FUNDING OPPORTUNITIES

- Explore priorities, opportunities, and strategies with leaders from NIH institutes – with a focus on how LA's diverse population represents a major priority for NIH funders and opportunity for LA founders
- Moderated by Carlos Gutierrez, Chief Strategy Officer, Larta Institute

Panelists include:

- Taryn Aubrecht, PhD, Health Program Specialist, National Institute of Neurological Disorders & Stroke (NINDS)
- LCDR Michael Banyas, USPHS, MPA, MA, SBIR Program Manager, National Institute of Minority and Health Disparities (NIMHD)
- Joshua Hooks, PhD, AAAS Science and Technology Policy Fellow, National Institute on Aging (NIA)
- Jain Krotz, PhD, Health Scientist Administrator, National Heart Lung and Blood Institute (NHLBI)

Note: Due to NIH travel schedules, participants are subject to change.

4:00pm NON-DILUTIVE FUNDING STRATEGIES

Hear from experienced founders and advisors on best practices for non-dilutive funding

Moderator: Stacy Feld, Regional Head, West North America, Johnson & Johnson Innovation

Panelists include:

- Rupak Doshi, CEO, OmniSync
- Earle Hager, Managing Partner, The Neutrino Donut, LLC
- Alborz Mahdavi, VP, Protomer Technologies, Eli Lilly and Company
- Joseph Schinaman, PhD, Chief Scientific Officer, Petro Bio

4:45pm AMGEN GOLDEN TICKET ANNOUNCEMENT

4:50pm ROUNDTABLE DISCUSSIONS

Meet our experts to explore specific ways that you can engage with them directly

RESEARCH SHOWCASE A

Artistry, 2nd Floor, South Wing

All Research Showcases are approximately 75 minutes each and may include a mix of

- **Roundtable Discussions**
- **Panels**
- **Scientific Research Posters**

1:43pm **RESEARCH SHOWCASE: METABOLISM**

Artistry, 2nd Floor, South Wing

Roundtable Discussions Led by Orian Shirihai, Professor of Medicine and Molecular and Medical Pharmacology & Chair and Professor, Endocrinology, Diabetes and Hypertension, UCLA

1:45pm **LIVER DISEASE**

- Discussion Leads:
  - Rajat Singh, Professor of Medicine & Director of Program in Basic Liver Research, UCLA
  - Joseph Pisegna, Professor, Division of Digestive Diseases, Department of Medicine and Human Genetics, David Geffen School of Medicine, UCLA
- **Panelist:** Tari Suprapto, Director, Search & Evaluation (West), Novo Nordisk

2:30pm **NETWORKING BREAK**

2:45pm **OBESITY & DIABETES**

- Discussion Leads:
  - Erik Dutson, Health Sciences Clinical Professor, David Geffen School of Medicine, UCLA
  - Claudio Villanueva, Associate Professor, Department of Integrative Biology & Physiology, UCLA

Panelists include:

- Cynthia Hong, Director, Search & Evaluation, Novartis
- Kelly Kaihara, Director, Life Science Tools & Diagnostics, General Inception
- Tari Suprapto, PhD, RTTP, Director, Search & Evaluation (West), Novo Nordisk
- Murielle Veniant-Ellison, Scientific Vice President, Global Research, Amgen

3:30pm **NETWORKING BREAK**

3:45pm **MYOPATHIES**

- Discussion Lead: Andrea Hevener, Endowed Chair in Molecular/Cellular Endocrinology, UCLA
- **Panelist:** Rachelle Crosbie, Professor, Department Chair, Integrative Biology and Physiology, UCLA

4:30pm **NETWORKING BREAK**

4:45pm **CANCER & IMMUNO-METABOLISM**

- Discussion Lead: Andrew Goldstein, Assistant Professor in the departments of Molecular, Cell & Developmental Biology and Urology, UCLA
- **Panelist:** Jim Johnston, CSO, ImmPACT Bio

RESEARCH SHOWCASE B

Centennial Ballroom AB, 1st Floor

1:45pm **RESEARCH SHOWCASE: REGENERATIVE MEDICINE**

Centennial Ballroom AB/1st Floor

Each researcher will introduce their work and the group will discuss the translation of stem cell research into clinical trials and the commercialization of stem cell findings.

- Led by Thomas Rando, Director Broad Stem Cell Research Center, UCLA
- Yvonne Chen, Associate Professor, UCLA
- Denis Evseenko, Director of Skeletal Regeneration, USC
- Don Kohn, Distinguished Professor, Microbiology, Immunology and Molecular Genetics, UCLA
- Antoni Ribas, Professor of Medicine, Molecular and Medical Pharmacology, UCLA
- Lili Yang, Associate Professor, Microbiology, Immunology and Molecular Genetics, UCLA

2:40pm **POSTER SESSION**

3:00pm **NETWORKING BREAK**

3:10pm **RESEARCH SHOWCASE: IMMUNITY, INFLAMMATION, INFECTION, AND TRANSPLANTATION (I3T)**

Centennial Ballroom AB/1st Floor

- Led by
  Manish Butte, Professor, Pediatrics, UCLA
  Dino Dicarlo, Professor/Vice Chair Grad Education, UCLA
- Joe de Rutte, Co-Founder and CEO, Partillion Bioscience
- Steven Jonas, Clinical Instructor, Pediatrics, UCLA
- Negin Majedi, CEO, Symphony Biosciences
- Andre Nel, Director of Research, CNSI at UCLA
- Phil Scumpia, Assistant Professor-in-Residence, Medicine, UCLA
- Lili Yang, Associate Professor, Microbiology, Immunology and Molecular Genetics, UCLA

4:25pm **NETWORKING BREAK**

4:35pm **RESEARCH SHOWCASE: ONCOLOGY**

Powered by TORL BIOTHERAPEUTICS

Centennial Ballroom AB/1st Floor
UCLA Jonsson Comprehensive Cancer Center

PI Spotlights:

- Dr. Anna Wu, Chair and Professor, Department of Immunology & Theranostics, City of Hope
- Dr. Xiuli Wang, Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
- James Turkson, PhD, Professor of Medicine, Associate Director for Diversity, Equity, and Inclusion, Cedars Sinai

4:50pm **ACCELERATING INNOVATION IN ONCOLOGY PANEL**

- Led by Edward Garon, Professor, Medicine, UCLA
- Steve Rosen, Provost & Chief Scientific Officer, City of Hope
- Cristina Puig Saus, Assistant Adjunct Professor, Medicine, UCLA
- David Shackelford, Associate Professor, Medicine, UCLA
- Dennis J. Slamon, MD, PhD, Director of Clinical/Translational Research, UCLA Jonsson Comprehensive Cancer Center

5:30pm **POSTER SESSION**

Schedule and Speakers subject to change.

RESEARCH SHOWCASE C

Centennial Ballroom CD, 1st floor

1:45pm **RESEARCH SHOWCASE: CARDIOVASCULAR**
Centennial Ballroom CD/1st Floor

peakers will present early technology all the way through technology that is ready for FDA submission

- Led by Arjun Deb, Professor, Cardiology, UCLA
- Hooman Allayee, Professor of Populations & Public Health Sciences and Biochemistry & Molecular Medicine, USC
- Jau-Nian Chen, Professor, Molecular, Cell, and Developmental Biology, UCLA
- Ahmed Ibrahim, Assistant Professor, Smidt Heart Institute, Cedars Sinai
- Jake Lusis, Professor, Departments of Medicine, Human Genetics and Microbiology, Immunology & Molecular Genetics, UCLA
- Julia Mack, Assistant Adjunct Professor, Medicine, UCLA

3:00pm **NETWORKING BREAK**

3:10pm **RESEARCH SHOWCASE: CLINICAL TRIAL ACCESS & ENROLLMENT**
Centennial Ballroom CD/1st Floor

- Led by Arash Naeim, Professor-in-Residence, Medicine, UCLA
- Sylvia Ferullo, Clinical Trial Navigator, Division of Hematology/Oncology, UCLA DGSOM
- Maria Garcia-Jimenez, Health Sciences Clinical Instructor, UCLA; Director of Oncology Research, Olive View - UCLA Medical Center
- Edward Garon, Professor, Medicine, UCLA
- Zul Surani, Associate Director of Community Outreach and Engagement & Cancer Research Center for Health Equity, Cedars-Sinai
- Maria Velez Velez, Fellow, Division of Hematology Oncology, UCLA
- Kabir Yadav, Vice Chair for Research & Academic Affairs/Professor of Clinical Emergency Medicine, UCLA

4:25pm **NETWORKING BREAK**

4:35pm **RESEARCH SHOWCASE: NEUROSCIENCE**
Centennial Ballroom CD/1st Floor
Neurotechnologies: Exploring the Future of Implantable Neural Devices

- Led by Nanthia Suthana, Associate Director, Neuromodulation Division, Jane and Terry Semel Institute for Neuroscience & Human Behavior, UCLA

  Brain to Body: Integrating implantable neurotechnologies and wearables
- Tyson Aflalo, Scientist, Convergent Research
  Creating scientific tools to inform next-generation neural interfaces
- Dejan Markovic, Professor, Samueli School of Engineering, UCLA
  The future of closed-loop neuromodulation technology
- Maryam Shanechi, Professor and Viterbi Early Career Chair, Viterbi School of Engineering, USC
  Next-generation neurotechnology to treat mental health conditions

Schedule and Speakers subject to change.

LABEST 2023 CLOSING RECEPTION

5:30pm JOIN US FOR DRINKS, BITES, NETWORKING AND LIVE JAZZ!

Centennial Terrace/3rd Floor

LABEST 2023 EXHIBITORS

1st Floor (Open 8:00 am - 4:45 pm)

A2 Bio
Abbott Construction
Amgen
Appia Bio
Breakthrough Properties
Cal State LA
Cedars Sinai
Charles River
Genentech
ImmPACT Bio
Johnson & Johnson Innovation
Kite, A Gilead Company
Landmark Bio
Pearl Cohen
UCLA Technology Development Group
Xencor

2nd Floor (Open 11:30 am - 5:00 pm)

Biocom CA
BioscienceLA
California Life Sciences
California NanoSystems Institute at UCLA
City of Hope (private room)
Cvent
Keck School of Medicine of USC (private room)
LARTA Institute
Lundquist Institute
Merck
UCLA Clinical and Translational Science Institute
UCLA Health/Biodesign

Treatment for Intellectual Disability Syndrome (Case ID: 2019-720 and 2020-777)

Inventors: Bill Lowry; Mike Jung; Bennett Novitch; Valerie Arboleda



INNOVATION

Intellectual Disability (ID) affects more than 100 million people globally and imposes a heavy economic burden of $14.7 billion annually on families and health systems. IDs, including Rett syndrome, Down syndrome, and fetal alcohol syndrome, are caused by mutations in epigenetic regulatory proteins. Recently these mutations have been implicated in causing the premature aging, or senescence, of neurons primarily located in the brain. However, drug development to treat such disorders has been significantly hindered by the difficulty in developing therapeutic compounds that are able to reach neurons in the brain. This is because of a tightly regulated cellular barrier that divides the vascular system from the central nervous system called the blood-brain barrier (BBB). Therefore, towards the development of curative drugs for IDs, crossing the BBB is of crucial importance.

UCLA researchers, led by Dr. William Lowry and Dr. Michael Jung, have discovered a library of compounds with the potential to reverse neuronal senescence and treat ID. Focusing on Rett syndrome for their studies, they developed Rett-derived human organoid models that allow screening of senescence inhibitors in the context of ID. Applying these models, they screened 45 molecules for senescence inhibition and identified 14 that successfully inhibited senescence, promoted dendritic branching, and restored brainwaves. Of those molecules, one novel compound was found to effectively penetrate BBB in-vivo in murine models.

These results indicate that compounds that reverse neuronal senescence and penetrate BBB could be effective for treating Rett syndrome. While other ID syndromes are caused by mutations in different epigenetic regulatory proteins, they all present with similar types of neuronal stress and similar neurological phenotypes. Therefore, the compounds identified here that reverse neuronal stress in models of Rett Syndrome could also alleviate ID syndrome symptoms in a wide variety of disorders.

POTENTIAL APPLICATIONS

- Novel long-term therapy for ID
- Human organoid models can be utilized in high-throughput platforms to develop novel therapeutic strategies for ID and broader CNS diseases
- High therapeutic value of anti-senescence drugs towards treating age-related diseases such as Alzheimer's or atherosclerosis

ADVANTAGES

- Compounds directly target the root cause of ID by reversing senescence
- Compounds serve an untapped therapeutic market with no currently approved treatment
- Organoids are physiologically relevant in vitro models

For more information, contact:

William Decker or PJ Ward
william.decker@tdg.ucla.edu or
peijean.ward@tdg.ucla.edu

Antisense oligonucleotide drugs (Case ID: 2018-717 and 2020-916)

Inventors: Feng Guo; Carrie Miceli; Yan Li; Florian Barthélémy



INNOVATION

RNA molecules play a critical role in the development of many diseases, such as cancers and RNA viral infections, making them excellent therapeutic targets. Technologies of targeting RNAs open new opportunities for therapeutic intervention, especially for genes that produce proteins previously deemed to be undruggable. Antisense oligonucleotides (ASOs) are single-stranded synthetic oligonucleotides that specifically bind target RNAs and elicit desired biological and therapeutic effects.

Recently, several ASO drugs have been approved by the FDA; however, current ASO Designs target RNA as a linear string i.e., 1D design strictly follows the rule of Watson-Crick (WC) base pairing. However, viral RNAs often fold into secondary and tertiary structures that can interfere with ASO hybridization. Key challenges of current ASO designs include variable binding affinity and specificity, relying on high-volume screening to identify leads, limitations in affinity and specificity resulting in narrow therapeutic windows, and the requirement for high concentration contributes to delivery problems.

UCLA researchers led by Dr. Feng Guo and Dr. Carrie Miceli have developed a three-dimensional (3D) structured-based method for designing ASOs. This new approach enables ASOs to bind with enhanced affinity and specificity; thus, allowing structured RNA to be targeted.

APPLICATIONS

- Treat a host of diseases that are specifically regulated by almost any target RNAs

ADVANTAGES

- Enhanced binding affinity and specificity to target RNAs
- Easy and rapid determination of 3D structures
- Wide applicability across a variety of diseases

For more information, contact:

Dan-Oscar Antson or PJ Ward
dan-oscar.antson@tdg.ucla.edu or
peijean.ward@tdg.ucla.edu

In situ vaccination with CXCL9/10 gene modified dendritic cells for advanced stage non-small cell lung cancer (Case ID: 2018-912 and 2019-601)

Inventors: Steven Dubinett; Bin Liu; Raymond Lim



INNOVATION

Lung cancer is the leading cause of cancer death worldwide, with a 5-year overall survival rate of 17% and 6% for metastatic disease. While lung cancers are responsive to PD-1 checkpoint blockade therapy, only 20% of patients respond to anti-PD-1 monotherapy due to primary, adaptive, or acquired resistance to the treatment. Thus, effective cancer immunotherapy requires methods to restore deficits in tumor antigen presentation and functional antitumor effector activities.

CCL21 is a secondary lymphoid chemokine that, upon binding to the CCR7 gene receptor, functions as a chemo-attractant for mature dendritic, naïve, and memory T cells, enhancing cell-mediated immunity against tumor cells. Intratumoral administration of CCL21 gene-modified dendritic cells (AdCCL21-DC) leads to increases of CD4+, CD8+, and CD11c+DEC205+ DCs infiltration of the tumor, decrease of immune-suppressive molecules in the tumor microenvironment, as well as reduction of tumor burden in the murine lung cancer model. More importantly, intratumoral administration of AdCCL21-DC also enhances CD8+ T cell infiltration and increased tumor PD-L1 expression in advanced non-small cell lung cancer (NSCLC) patients.

Researchers at UCLA have shown that advanced NSCLC patients with baseline PD-L1 expression benefit the most from anti-PD-1 treatment, suggesting responses to PD-1/PD-L1 blockade are more likely in the setting of tumor PD-L1 expression and a pre-existing T lymphocyte infiltration of the tumor. Indeed, UCLA researchers have shown that AdCCL21-DC and anti-PD-1 combination therapy outperforms both mono-therapies in syngeneic murine lung cancer models. Specifically, the combination therapy significantly enhances the cytolytic activity of tumor-infiltrating lymphocytes (TILs) against the tumor, accompanied by a significant reduction in tumor volume and tumor growth.

APPLICATIONS

- Immunotherapy for NSCLC, melanoma, and other types of solid tumors

ADVANTAGES

- Improve clinical response to anti-PD-1/PD-L1 therapy
- Boosts local and systemic immune responses
- Reduce tumor burden and tumor growth

For more information, contact:

Tariq Arif
Business Development Officer
tariq.arif@tdg.ucla.edu

Leveraging the Gut Microbiome to Combat Obesity and Food Addiction (Case ID: 2020-129)

Inventors: Tien Dong; Arpana Gupta



INNOVATION

Obesity is a problem affecting millions with no widely available solutions. Obesity and its comorbidities pose a serious global health crisis. In 2016, about 2 billion adults, 18 years and older, were overweight. Of these, over 650 million were obese. This accounts for 39% of adults being overweight, and 13% being obese. These numbers are projected to continue to increase with rates as high as half of Americans being obese by 2030 and as high as 80% by 2050.

Food addiction is a major cause of obesity. Studies have shown that 30-50% of those who are overweight or obese have a food addiction. Food addiction is eating highly palatable foods (processed foods high in fat, sugar, and salt) when you are not hungry, as diagnosed using the Yale Food Addiction Scale. The diagnostic criteria for food addiction is based on the same criteria for other substance use disorders (i.e., alcohol, drugs, smoking). Food addiction affects the same regions of the brain as other addictive disorders.

A new pathway to combat both obesity and food addiction is through the brain-gut axis. UCLA researchers have shown there are 3 biological features of food addiction evident in the brain-gut axis. Using an untargeted metabolite assay examining >1000 different metabolites, food addiction was inversely associated with 1 metabolite: a neuroprotective metabolite called indolepropionate. Stronger connections in the brain's reward center, visible via MRI. Because indolepropionate is only created by our gut bacteria, UCLA researchers examined the microbiome of patients with food addiction and found a reduction in 3 protective bacteria.

APPLICATIONS

- Therapeutic Drug target
- Non-invasive diagnostic screening tool to rule out obesity and type 2 Diabetes
- Obesity and Food Addiction Treatment
- Probiotics
- Biomarker screening

ADVANTAGES

- A potential compound used to alter gut microbiome to progress obesity
- Develops a screen to identify patients with food addiction
- First of its kind compound for patients with food addiction

For more information, contact:

Earl Weinstein
Business Development Officer
earl.weinstein@tdg.ucla.edu

A Hexokinase 2 Inhibitor to Treat Hepatocellular Carcinoma (Case ID: 2020-788)

Inventors: Peter Clark; Robert Damoiseaux; Varghese John; Richard Finn



INNOVATION

Hepatocellular carcinoma (HCC) has a 5-year survival rate of <15%. The current standard of care for HCC includes chemotherapies such as atezolizumab/bevacizumab, sorafenib/Lenvatinib, and/or immunotherapy regimen of nivolumab, pembrolizumab, nivolumab + ipilimumab). However, none of the current therapies have biomarkers to allow for patient selection. Thus, new therapies are needed to treat HCC. Hexokinase 2 (HK2) is a well-validated target in HCC i.e., up to 40% of HCC express high levels of HK2, which is required for the growth of these tumors.

UCLA researchers led by Dr. Peter Clark have developed a small molecule inhibitor of Hexokinase 2 (HK2), an essential enzyme in over 40% of HCC, to treat HCC. They have developed and validated a high-throughput assay (based on a commercial assay) for identifying small molecule inhibitors of HK2. The cellular screen allows them to identify compounds that block HK2 activity through mechanisms other than direct binding to the enzymatic pocket.

APPLICATIONS

- Precision medicine approach i.e., enables targeting of select patient-population that would benefit from targeting Hexokinase 2
- 18F-FDG PET can be used to non- invasively measure hexokinase activity in patient tumors

ADVANTAGES

- Identifies selective hexokinase inhibitors
- The assay is reproducible and precise
- Targets an orthogonal pathway to current therapies
- Cost-effective

FOR MORE INFORMATION, CONTACT:

Dan-Oscar Antson or PJ Ward
dan-oscar.antson@tdg.ucla.edu or
peijean.ward@tdg.ucla.edu

Targeting RNA Binding Proteins in Cancer Cells (Case ID 2019-831)

Inventors: Dinesh Rao; Neil Garg; Robert Damoiseaux



INNOVATION

Chromosomal rearrangements of mixed-lineage leukemia (MLL/KMT2A) gene are recurrently found in a subset of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and rarely in acute leukemia of ambiguous lineage. Despite recent advances in therapeutic approaches, patients with MLL-rearranged (MLLr) leukemia have poor outcomes, a high risk of relapse, and show resistance to novel targeted therapies.

UCLA researchers led by Dr. Dinesh Rao have identified a novel RNA binding protein, IGF2BP3, which is overexpressed in multiple cancer types and not expressed in normal tissues. Preclinical studies conducted by Dr. Rao and colleagues showed that:

- On knocking out IGF2BP3 gene expression in-vitro and in-vivo
  - Leukemic cell growth decreased in-vitro
  - MLL-driven leukemia reduced, which increases survival in-vivo
  - Normal hematopoiesis was not affected in-vivo
- Overexpression of IGF2BP3 gene in vivo led to an increase in white blood cell (WBC) lineages

The above suggests that IGF2BP3 played a critical role in B acute lymphoblastic leukemia (B-ALL) with MLL translocations, thus making IGF2BP3 an important therapeutic target for rB-ALL MLL translocations. Dr. Rao and colleagues are currently developing a novel small molecule IGF2BP3 inhibitor that targets a pathway orthogonal to existing therapies, making it ideal for patients with refractory disease.

APPLICATIONS

- Orthog can be used to treated patients with refractory disease

ADVANTAGES

- Cost-effective
- Greater ease of adoption than existing therapies (i.e., CD-19 CAR-T)

For more information, contact:

Dan-Oscar Antson or PJ Ward
dan-oscar.antson@tdg.ucla.edu or
peijean.ward@tdg.ucla.edu

Novel Antiviral Compounds to Treat Enterovirus Infections (Case ID: 2012-260 and 2015-829)

Inventors: Paul Krogstad; Michael Jung; Jun Zuo; Yanpeng Xing



INNOVATION

Researchers in UCLA's Department of Molecular & Medical Pharmacology and Department of Chemistry & Biochemistry have used a rapid, live virus assay to help design and test potent enterovirus inhibitors. The compounds are unlike any previously described inhibitors of EV replication, and exhibit very potent activity against coxsackievirus B. Using these novel analogues, the researchers designed and synthesized several EV growth inhibitors that exhibit more potent activity and broader spectrum of activity than currently available therapeutics. The antiviral agents can be altered and expanded to other members of picornavirus family, or other viruses with similar replication strategies. These antiviral agent derivatives could become the basis for development of medications to combat different classes of viral infections.

APPLICATIONS

- Treatment of various EV infections
- Development of antiviral agents for treatment of other viruses

ADVANTAGES

- Compounds exhibit potent antiviral activity
- Compounds exhibit a broad range of antiviral activity
- Compounds are applicable to large number of medically relevant enteroviruses
- Antiviral analogues have the potential to be expanded to treat other families of viruses

FOR MORE INFORMATION, CONTACT:

William Decker or Peijean (PJ) Ward
william.decker@tdg.ucla.edu or
Peijean.ward@tdg.ucla.edu



We are the Advocate for Life Science in California

Representing over 1,700 members of the life science community statewide

Biocom California is the indisputable leader in accelerating life science in California. We accelerate our members' success by advocating for innovation, removing barriers to doing business, and connecting people, talent, and capital.

Learn more at **www.biocom.org**

Biocom California

Research and Development

We are rapidly turning breakthrough therapies into lifesaving treatments.

- We have three on-site cGMP manufacturing facilities.
- We have a powerful in-house research incubator.
- We were awarded $214 million in research grants last year.
- We have filed 145 IND applications.
- We earned $2.9 billion in royalties and licensing over the past decade.
- We hold more than 450 patents for technology invented here.

Find out more at CityofHope.org/gmp-manufacturing-facility.

Keck School of Medicine of USC

MESH Strategic Partnerships

We enable transformative innovation through the power of partnership with personalized services for USC faculty and industry.

Let's Connect and Collaborate!



Visit the USC MESH room on the second floor
https://keck.usc.edu/mesh-academy/get-started/

Cedars Sinai

UCLA TECHNOLOGY DEVELOPMENT GROUP

UCLA Technology Development Group are the producers of LABEST 2023. This is the fifth year of the conference and we are proud to see how it has grown. LABEST brings together bioscience researchers, faculty, industry and investors for a day of conversation and connection. Thank you for attending the event.

FACTS & FIGURES

UCLA ranks among the nation's Top Five institutions in research funding.

UCLA TDG FY2022

20
Start Ups

32
Exclusive Licenses

338
Invention Disclosures

$70M
Industry Sponsored Research Awards

UCLA RANKED

#9
Heartland Forward Tech Transfer & Commercialization Report

#12
Pitchbook Startup Founders

UCLA TECHNOLOGY DEVELOPMENT GROUP SCOPE OF ACTIVITIES

Commercially evaluating new technologies

Determining patentability and commercial value

Prosecuting patents

Marketing and licensing inventions

Facilitating UCLA faculty startups

Engaging industry to facilitate research collaboration

Negotiating license agreements and Material Transfer Agreements

Receiving and distributing royalties and other income to the inventors, UCLA campus and its departments

Producing the UCLA MedTech Partnering Conference and the Los Angeles Bioscience Ecosystem Summit (LABEST)

TDG.UCLA.EDU

CONTACT US INFO@TDG.UCLA.EDU

PRODUCED BY:

UCLA TECHNOLOGY DEVELOPMENT GROUP

LA BIOSCIENCE ECOSYSTEM SUMMIT TWENTY23™

UCLA

UCLA TECHNOLOGY DEVELOPMENT GROUP (TDG) promotes UCLA innovation, research, education and entrepreneurship to benefit society. Working with UCLA TDG helps facilitate the translation of UCLA discoveries into new products and services that create economic value to support UCLA's scholarly and educational missions. The UCLA TDG office manages a large portfolio of technologies and license agreements and has a rich history of startup company formation.

CONNECT WITH UCLA TDG:

Visit us at tdg.ucla.edu

Contact us at marketing@tdg.ucla.edu

Connect with us @UCLATDG

#LABEST2023

UCLA Technology Development Group
10889 Wilshire Blvd. Suite 920
Los Angeles, CA 90095
310-794-0558